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Background: Improvement in quality of life together with better survival are the ultimate goals in the treatment of
pulmonary arterial hypertension (PAH) patients. The objective of this study was to evaluate the health-related quality
of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify
the prognostic implication of this assessment.
Methods: Fifty-four consecutive newly diagnosed PAH patients (WHO classification group I) in a single PAH
reference center were included. Patients were evaluated at baseline for clinical and hemodynamic parameters, and
they subsequently received first-line therapy with either an endothelin receptor antagonist or a phosphodiesterase-5
inhibitor. After 16 weeks of specific PAH therapy, all patients were re-evaluated using a 6MWT and a SF 36 questionnaire,
and then they were followed up for at least 36 months.
Results: After treatment, the patients demonstrated an improved 6MWT (414 ± 124 m vs. 440 ± 113 m, p = 0.001).
Specific PAH therapy also improved the HRQL scores.
Patients with a baseline Physical Component Score (PCS) higher than 32 had a better survival rate than those who had a
score under 32 (p = 0.04). Similarly, patients with a PCS of at least a 38 after the 16 week therapy period had a better
survival rate when compared with those who did not achieve this value (p = 0.016). Unlike the absolute PCS values, the
post-treatment PCS variability was unable to predict better survival rates (p = 0.58).
Conclusions: Our findings suggest that HRQL is associated with prognosis in PAH. Furthermore, achieving pre-determined
PCS scores might represent a specific goal to be reached in treatment-to-target strategies.
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Pulmonary arterial hypertension (PAH) is a chronic dis-
ease caused by elevated pressure in the lung vasculature,
eventually leading to the right ventricle failure and death
due to circulatory collapse [1]. PAH is a rare condition
with an annual incidence of 1.1 to 7.6 cases per million
and a prevalence of 15 to 26 cases per million [2]. Con-
sequently, the development of clinical trials with useful
endpoints is challenging because mortality, as the pri-
mary endpoint, is usually not feasible. Therefore, alter-
native methods for evaluating the clinical responses to* Correspondence: souza.rogerio@me.com
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article, unless otherwise stated.specific PAH therapies were widely used in the design of
randomized, controlled trials and in clinical practice [3].
Studies that addressed targeted PAH therapies, such as
prostanoids [4], endothelin receptors antagonists (ERA)
[5], and phosphodiesterase-5 inhibitors (PDE5i) [6], have
demonstrated that several parameters, including the
New York Heart Association functional class assessment,
the six-minute walk test (6MWT), serum biomarkers
(BNP and NT-ProBNP) [7-9] and invasive hemodynamic
(Cardiac Index, Mean Pulmonary Artery Pressure and
Right Atrium Pressure) measurements, closely associate
with disease severity and are directly improved by medical
treatments suggesting a potentially positive influence of
these therapies on PAH patients’ mortality [10].
Nevertheless, the main objective of specific therapies
for PAH patients was to improve not only the quantitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tients are well known to have a severely impaired
health-related quality of life (HRQL) [11]. Reports of
evaluation tools that specifically address the impaired
HRQL induced by PAH are still limited in the literature
[12,13] and are not routinely employed in general prac-
tice in PAH patients. The development of PAH treat-
ment strategies that could simultaneously evaluate both
the quantity and quality of life would be potentially use-
ful in the clinical management of this disease.
Quality of life can be evaluated in several chronic dis-
eases using specific and validated inquiries such as the
Short-Form 36 Health Survey (SF-36) [14]. This highly
reproducible, well-known, non-invasive and frequently
used survey, for such evaluations, is widely available in
several different languages [15]. Although specific PAH
therapies have already been demonstrated to improve
HRQL [16-19], the association of this improvement and
survival has not been properly addressed.
The aim of this study was to evaluate the impact of
targeted PAH therapies on the HRQL using the SF-36
and addressing HRQL association to survival.
Methods
Patient population
Newly diagnosed PAH patients (group I of the Dana
Point Classification system) [20] followed in a large PAH
reference center (Heart Institute) in São Paulo, Brazil,
were included in this study. The protocol was approved
by the Institutional Review Board.
The baseline patient evaluations included obtaining in-
formation on demographics and medical histories and
included the New York Heart Association (NYHA) func-
tional class assessments, physical examinations and rou-
tine laboratory tests. Data from 6MWT assessments
[21], quality of life questionnaires [19] and right heart
catheterizations using standard techniques were also ob-
tained [22].
The PAH patients’ quality of life was assessed using
the SF 36 questionnaire, which consists of 36 questions
covering eight domains. Four domains are projected to
reflect the impact of the disease on the physical compo-
nent of the patients life (Physical Component Score –
PCS), and the four remaining domains are projected to
reflect the impairment caused by the disease on mental
status (Mental Component Score – MCS). The scores
were converted to a 100-points score scale where higher
scores indicated a better QOL. The SF-36 questionnaire
was given by a person trained to use the QOL assess-
ment tool [15] and was chosen because it had been vali-
dated for use in the native language of the patients who
comprised the study [23].
Patients with PAH are defined as having a mean pul-
monary artery pressure (mPAP) > 25 mmHg with anormal pulmonary artery occlusion pressure (PAOP <15
mmHg) [20]. Patients were classified as having idio-
pathic pulmonary arterial hypertension (IPAH) when
PAH was diagnosed in the absence of chronic thrombo-
embolic pulmonary hypertension and was not associated
with significant left heart or lung disease or with other
known conditions, including HIV infection, portal hyper-
tension, congenital systemic-pulmonary shunts, connect-
ive tissue diseases and exposure to appetite suppressants.
Patients were classified as having schistosomiasis-
associated PAH (Sch-PAH) when the presence of PAH
was associated with liver ultrasonographic observations
that were highly suggestive of mansonic schistosomiasis
(left lobe enlargement and/or periportal fibrosis). Add-
itionally, the patients must demonstrate at least one of
the following features: 1) the endemic regional expos-
ure to schistosomiasis, 2) previous treatment for schis-
tosomiasis and 3) the presence of Schistosoma mansoni
eggs in the stool following examinations or rectal biop-
sies [24,25].Treatments
In the absence of any contraindication (e.g., high risk of
gastrointestinal bleeding or presence of esophageal vari-
ces) the patients received oral anticoagulation; diuretics
and oxygen were prescribed as needed.
Patients received a PAH first-line therapy of either an
ERA or a PDE5i. The choice between the agents was
based on the drug availability at our facility. After 16
weeks of specific PAH therapy, all patients were re-
evaluated by means of the 6MWT and the SF 36 HRQL
questionnaire. Patients were then followed up for up to
36 months for survival analysis.Statistical analysis
Analysis was performed using the SPSS 15 statistical
package (SPSS, Inc., Chicago, IL). All continuous vari-
ables are expressed as median ± SD, whereas the categor-
ical data are presented as proportions. The Cronbach’s α
coefficient was calculated for all SF 36 scores to verify
the questionnaire reproducibility and reliability, and
values higher than 0.7 were considered satisfactory.
To compare the baseline and post-treatment charac-
teristics, a paired t-test was used. For survival analysis,
the first hemodynamic evaluation was considered to be
the date of diagnosis. All-cause mortality was used be-
cause of the lack of information about the specific cause
of death in several cases. No patients were lost to
follow-up during the study period. The patient survival
was estimated using the Kaplan-Meier method, and
the log-rank test was applied to compare these curves.
A p-value of less than 0.05 was considered as statisti-
cally significant.
Fernandes et al. Health and Quality of Life Outcomes 2014, 12:130 Page 3 of 6
http://www.hqlo.com/content/12/1/130Results
The study population consisted of 54 PAH patients. The
baseline clinical, functional and hemodynamic data are
shown in Table 1 and are compatible to previously pub-
lished series for PAH patients.
After the 16-week treatment period using an ERA (in
85% of all cases) or a PDE5i (in the remaining 15%),
patients demonstrated a significantly improved 6MWT
(414 ± 124 m vs. 440 ± 113 m, p = 0.001) as well as in
functional class (p = 0.02). Specific PAH therapy also
improved the HRQL scores as evaluated by the SF 36
for all the domains except for bodily pain (Figure 1).
The Cronbach’s α coefficient was found to be 0.852
and considered adequate. Interestingly, baseline PCS
correlated with 6MWD (r = 0.493, p < 0.01) and also
with functional class (r = -0.576, p < 0.01).
Furthermore, the HRQL scores were able to discrimin-
ate between patients with a better survival both in the
baseline and in the post-treatment periods. Patients with
a baseline PCS higher than the median value (32) had a
significantly improved survival (p = 0.04, Figure 2). A
similar pattern was found in the post-treatment evalu-
ation; patients who reached more than the median
post-treatment PCS value (38) had a better survival
rate when compared to those who did not reach thisTable 1 Baseline clinical and hemodynamic data (n = 54)
Age (years) 44 ± 12
Sex (f/m) 45/9
Etiology n (%)
Idiopathic 37 (68)
Associated to
Schistosomiasis 7 (13)
CTD 8 (15)
CHD 2 (4)
NYHA functional class n (%)
II 14 (26)
III 28 (52)
IV 12 (22)
6MWT (m) 418 ± 121
mPAP (mmHg) 64 ± 17
PAOP (mmHg) 10 ± 2
Cardiac output (L/min) 4 ± 1
PVR (WU) 15 ± 8
Therapy n (%)
ERA 46 (85)
PDE-5 inhibitors 8 (15)
CTD Connective tissue disease, CHD Congenital heart disease, NYHA New York
Heart Association, 6MWT Length in non-encouraged six-minute-walk test, RAP
Right Atrial Pressure, mPAP Mean Pulmonary Artery Pressure, PAOP Pulmonary
Artery Occlusion Pressure, PVR Pulmonary Vascular Resistance, ERA Endothelin
Receptor Antagonists, PDE-5 Phosphodiesterase-5 inhibitor.threshold (p = 0.016, Figure 3). Notably, the absolute
change in PCS after treatment was not predictor of
survival in this study (p = 0.58, Figure 4).
Discussion
This study demonstrated the association of HRQL as-
sessment, more specifically, the use of the SF 36 ques-
tionnaire, with prognosis in PAH. The baseline HRQL
measurements can distinguish a high-risk subgroup of
PAH patients with a poor survival outlook. Furthermore,
HRQL might also represent a viable treatment goal be-
cause reaching a specific post-treatment threshold on
the PCS was associated with better survival.
The aim of specific PAH therapy is to improve patient
survival. However, despite all the recent advances in
diagnostic and therapeutic modalities for PAH, the mor-
tality rate remains high, with a 5-year survival of 57%
[26]. Despite the need for improved treatment strategies,
these data also reinforce the significance of improving
the HRQL for such a relentless and progressive disease.
Our study attempts to concatenate both survival and
quality of life evaluations as a result of specific drug
therapy. While attempting to improve the HRQL and es-
tablishing harder endpoints for clinical therapy, it is pos-
sible that better survival rates might also be achieved.
Previous studies have already demonstrated that the
HRQL of PAH patients is severely reduced when com-
pared to healthy individuals [11]. PAH patients present
with reduced physical mobility, significant dyspnea and
increased difficulties in social interactions. Some trials
involving PAH patients, when evaluating the response to
different therapies, used HRQL questionnaires as second-
ary endpoints but reached variable results. One study
showed that the HRQL improved modestly after bosentan
therapy and this improvement was stable for 3 months
[16]. The same response pattern was also described with
another ERA, sitaxsentan [27]. However, the HRQL
remained unchanged in other clinical trials using thera-
peutic drugs known to be effective for PAH patients such
as treprostinil [4] and ambrisentan [28]. Nevertheless, re-
cent systematic review on the effect of targeted therapies
in HRQL of PAH patients demonstrated that HRQL con-
sistently improved after specific intervention, even consid-
ering the heterogeneity of the instruments used for quality
of life evaluation among the different studies [29]. In our
study, except for bodily pain, all domains significantly im-
proved after treatment with specific PAH therapies, result-
ing also in a significant improvement in the physical
component score as in the mental component score.
Recently, Roman et al. described the HRQL of PAH
and chronic thromboembolic pulmonary hypertension
(CTEPH) Spanish cohorts and described similar baseline
results to those in our study [30]. In the Roman et al.
study, both the SF-36 and EuroQol 5D questionnaires
Figure 1 SF-36 score domains variations after specific PAH therapy for 16 weeks (* p < 0.05). PF – Physical Function, RF – Role Physical,
BP – Bodily Pain, GH – General Health, MH – Mental Health, RE – Role Emotional, SF – Social Function, VT – Vitality, PCS – Physical Component
Score, MCS – Mental Component Score.
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Nevertheless, our study is the first to demonstrate that
the clinical response to specific PAH therapy could be
effectively measured using a SF-36 questionnaire. In our
study, the baseline physical score component and the
PCS after 16 weeks of specific PAH treatment was asso-
ciated with patient survival. In a pattern similar to one
previously described for the 6MWT [31], the absolute
variation of PCS after treatment was not associated with
survival suggesting that achieving a specific PCS thresh-
old is more important than improving the PCS itself to
determine a better prognosis. This is the first time that a
specific goal associated to HRQL is described in addition
to others previously defined in the literature [32].Figure 2 Kaplan Meier survival rates according baseline SF-36
Physical Component Score (PCS). Log rank test, p = 0.04.For 6MWT, it has been previously suggested that im-
provements of 33 m would represent the minimal im-
portant difference (MID) to reflect improvements in
the quality of life of PAH patients [17]. A more recent
analysis of the raw data from ten different trials tried
to establish the relationship between the changes in
6MWD and the probability of clinical deterioration to
occur [33]. In this study, Gabler et al. demonstrated
that on average 6MWD improved by 22.4 m with active
treatment; however, this improvement accounted only for
a small proportion of the treatment effect, suggesting the
change in 6MWT would not represent a valid surrogate in
PAH, confirming the previous findings from Sitbon et al.Figure 3 Kaplan Meier survival rates according SF-36 Physical
Component Score (PCS) after 16 weeks of specific PAH therapy.
Log rank test, p = 0.016.
Figure 4 Kaplan Meier survival rates according variation of
SF-36 Physical Component Score (PCS) after 16 weeks of spe-
cific PAH therapy. Log rank test, p = 0.58.
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a minimum functional status should be reached in order
to reflect better prognosis.
A MID in SF-36 scores has been suggested for PAH.
Gilbert et al. mathematically determined the MID,
throughout distribution-based models, suggesting MID of
13 to 25, depending on the domain of the SF-36 [34].
No analysis on the physical or mental component
scores were reported. The same study suggested a MID
of 41m for the 6MWT. However, the analysis was
based solely on the distribution of the results, since
the authors had no surrogate marker to use as an an-
chor to determine the relevance of the MID, thus pre-
venting the extrapolation of the results; differently, our
study used survival as a hard endpoint for the analysis
of the minimum threshold in HRQL, more specifically
in PCS, that could reflect better long-term survival in
PAH.
In 2006 McKenna et al developed a HRQL scale specif-
ically for the PAH population using the Cambridge Pul-
monary Hypertension Outcome Review (CAMPHOR)
[13]. The CAMPHOR questionnaire comprises overall
symptoms (comprising Energy, Breathlessness and Mood
subscales), functionality and HRQL, and demonstrated
good values for the Cronbach’s α coefficient, and reprodu-
cibility. Recently, several studies used the CAMPHOR
scale in several cohorts across the world and validated the
questionnaire in German [35], French-Canadian [36] and
Swedish [37] languages. The CAMPHOR questionnaire
was also applied to different English-speaking PAH pa-
tient populations such as American [38], Canadian
[36], Australian and New Zealander [39] with good results.
However, the predictive value of CAMPHOR appears to be
restricted to baseline evaluations. Recently, McCabe et al
demonstrated that repeated CAMPHOR assessmentsover time did not add any predictive value for clinical
deterioration to that obtained at diagnosis in an IPAH
population followed for 8 years [40]. These data limit
the prospective utility of CAMPHOR assessments for
clinical follow-up.
This study has limitations that need to be acknowl-
edged. First, it was a single center study in a country
with a peculiar distribution of PAH etiologies where
schistosomiasis-associated pulmonary arterial hyperten-
sion holds high epidemiologic relevance [41-43]. Al-
though our center is the largest reference center in the
country, the potential selection bias associated with this
limitation should be taken into consideration when ex-
trapolating our results. Furthermore, we decided not to
use a health-related quality of life questionnaire specific
for PAH, but a general one, projected to evaluate chronic
diseases. Nevertheless, the SF-36 is the best-known and
studied HRQL questionnaire, worldwide; additionally, it is
rapid, easy and reliable.
Despite these limitations, our results support the asso-
ciation of PAH prognosis with general HRQL evaluation
with the SF-36 questionnaire, at baseline and after spe-
cific PAH therapies. Moreover, achieving pre-determined
PCS scores might represent a specific goal to be reached
in treatment-to-target strategies, as currently is recom-
mended for PAH.
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